GE Healthcare received FDA approval for DaTSCAN for priority review





GE Healthcare announced that the FDA has accepted the New Drug Application for DaTSCAN (Ioflupane I123 Injection) for priority review.  DaTSCAN is a radiopharmaceutical agent containing Ioflupane (¹²³I) in development for a proposed indication of the detection of loss of functional nigrostraiatal dopaminergic neurons by single photon emission computed tomography (SPECT) imaging in patients presenting with symptoms or signs suggestive of dopaminergic neurodegeneration.

Don Black, MD, head of R&D for GE Healthcare Medical Diagnostics said, We are very pleased that the FDA has accepted our NDA for DaTSCAN. Acceptance of the NDA filing for priority review is an important milestone for GE Healthcare, and we will continue to work with the FDA with the objective of making DaTSCAN available in the United States.

DaTSCAN has been available in Europe since 2000. In Europe, DaTSCAN is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum in patients with clinically uncertain Parkinsonian Syndromes in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson’s Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP). DaTSCAN is unable to discriminate between PD, MSA and PSP.  In Europe, it is also indicated to help differentiate probable dementia with Lewy bodies (DLB) from Alzheimer’s disease. DaTSCAN is unable to discriminate between DLB and Parkinson’s disease dementia.